Heart FailureSMILE™NCT02448342
Sensible Medical Innovations Lung fLuid Status Monitor Allows rEducing Readmission Rate of Heart Failure Patients
A study testing Remote Dielectric Sensing (ReDS) Wearable System in people with Heart Failure, run by Sensible Medical Innovations Ltd. at 41 sites in United States.
Trial summary
Multi center, randomized controlled study, to determine if a significant decrease in the rate of heart failure re-hospitalizations occurs during a follow-up period when - ReDS guided treatment is used as an adjunct to standard of care. Read more about this study
- Who is it for?
- Ages 21 years and older
- Conditions the study is for
- Heart Failure
- What is being tested?
- Remote Dielectric Sensing (ReDS) Wearable System
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 380 participants
- Where
- 41 sitesUnited States
- Study dates
- Sep 2015to 30 Nov 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Main Inclusion Criteria:
- Patient has signed informed consent and authorization to use and disclose health information.
- Patient's physical condition enables him to sit up and lay down with minimal assistance.
- Diagnosis of HF, with preserved or reduced LVEF, was made at least 30 days prior to enrollment.
- Patients with LVEF <40% must have been treated at least 30 days prior to enrollment with diuretics and beta-blocker (unless intolerant or contra-indicated) and an ACE-inhibitor or ARB (unless intolerant or contra-indicated).
- Patient is hospitalized for ADHF requiring significant alteration in heart failure treatment (i.e. diuretics or vasoactive drugs) or up to 10 days post-discharge from an ADHF admission.
- BNP ≥ 350 pg/ml (NT pro BNP > 1400 pg/ml) at enrollment (within 24h) and/or ≥750 pg/ml any time during the hospital stay (NT-pro BNP >3000 pg/ml).
Note that if a patient is enrolled during a clinic visit rather than during a hospitalization, then the BNP from the index admission is referenced.
Main Exclusion Criteria:
- Patient has had a cardiac transplantation or VAD implantation.
- CRT implantation within 90 days prior to screening or planned implantation during study duration.
- Current or past Pulmonary Embolism in the right lung. Notes: (i) Past pulmonary emboli are defined as identified <6 months prior to enrollment. (ii) past or current tiny, microscopic pulmonary emboli do not exclude a patient. (iii) if a ventilation-perfusion (VQ) scan shows that the lungs are clear, then the exclusion criteria is not met.
- Diagnosis of Severe Pulmonary Hypertension.
- STEMI and or CABG within 30 days of screening visit. Note: Type 2 MI due to ADHF is not an exclusion.
- Chronic renal failure with CrCl<25mL/min, as calculated by the Cockcroft-Gault formula.
- Chronic home IV therapy or cardiac inotropes or diuretics
- Physical deformity in the thorax area or lesion that may prevent proper vest application or adjustment (Severe scoliosis/ sensitive sternotomy lesion etc.).
- Illness/ Condition which may be aggravated or cause significant discomfort by the application of the vest (Rib fractures, with or without flail chest, Severe Osteoporosis).
- Impaired cognitive ability or any other state that may prevent full compliance with the study protocol, according to investigator's assessment.
- Patient's habitus out of range due to one or more of the following:
- Height less than 155cm or higher than 195cm (5.1; 6.4 feet respectively).
- BMI of less than 22 or more than 36. In case of BMI between 36-38, if the measured vest ruler is not >=4, the exclusion criteria is met.
- Congenital heart malformations or intra-thoracic mass that would affect the right lung anatomy (Dextrocardia, Lung Carcinoma etc.) including pacemaker box on the right side of the chest.
- Severe COPD, defined as chronic and continuous home use of O2 (O2 dependancy) and/ or oral steroids. Continuous is defined as 24hours a day, every day.
- Severe disease / conditions with life expectancy <6 months according to investigator's assessment.
- Patient is enrolled in another interventional study with permission of study manager (observational or registries are not excluded).
- Patient HF is managed remotely with another monitoring device or program (for example: Pulmonary/ Lt Atrial pressure monitoring, Weight scale, BNP or bioimpedance).
- Prisoners and ward of the state
Trial locations and contacts
41 sites in 1 country.
41 sites in 1 country
United States41 sites
Suma Health Services
Akron, Ohio, 44304
Piedmont Heart Institute
Atlanta, Georgia, 30309
University of Alabama
Birmingham, Alabama, 35294-0007
University of Chicago
Chicago, Illinois, 60637
Cleveland Clinic
Cleveland, Ohio, 44195
Dorothy M. Davis Heart & Lung Research Institute at The Ohio State University Wexner Medical Center
Columbus, Ohio, 43210-1252
The Ohio State University Wexner Medical Center
Columbus, Ohio, 43210-1252
Geisinger Medical Center
Danville, Pennsylvania, 17822
St Elizabeth Healthcare
Edgewood, Kentucky, 41017
Elmhurst Memorial Hospital
Elmhurst, Illinois, 60126
Northshore University HealthSystem
Evanston, Illinois, 60201
Advanced Heart Care Group
Fairview Heights, Illinois, 62208
Cedars Sinai
Hollywood, California, 90048
Memorial Regional Hospital
Hollywood, Florida, 33021
Encore Research Group
Jacksonville, Florida, 32207
Saint Luke's Hospital of Kansas City
Kansas City, Missouri, 64111
Scripps Memorial Hospital La Jolla
La Jolla, California, 92037
Lancaster General Health Hospital
Lancaster, Pennsylvania, 17603
Bryan Heart
Lincoln, Nebraska, 68506
North Shore University Hospital
Manhasset, New York, 11030
Virginia Cardiovascular Specialties
Midlothian, Virginia, 23112
Minneapolis Heart Institute Foundation
Minneapolis, Minnesota, 55407
Edward Heart Hospital
Naperville, Illinois, 60540
Centennial Medical Center - Sarah Cannon Research Institute
Nashville, Tennessee, 37203
Yale University Medical Center
New Haven, Connecticut, 06519
Long Island Jewish Hospital
New Hyde Park, New York, 11040
Mount Sinai Medical Center
New York, New York, 10029
Weil Cornell Medical Center
New York, New York, 10065
Lenox Hill Hospital
New York, New York, 10075
Drexel University Medical Center
Philadelphia, Pennsylvania, 19102
VA Pittsburgh Health System
Pittsburgh, Pennsylvania, 15240
Henrico Doctors' Hospital
Richmond, Virginia, 23229
Scripps Mercy Hospital San Diego
San Diego, California, 92103
UCSF Medical Center, Parnassus
San Francisco, California, 94143
Pacific Heart Institute
Santa Monica, California, 90404
Prairie Heart Institute / St. John's Hospital
Springfield, Illinois, 62701
St. Louis Heart and Vascular
St Louis, Missouri, 63136
MedStar Heart and Vascular Institute
Washington D.C., District of Columbia, 20010
Washington DC VA Medical Center
Washington D.C., District of Columbia, 20422
Geisinger Wyoming Valley Medical Center
Wilkes-Barre, Pennsylvania, 17822
Pinnacle Health Cardiovascular Institute
Wormleysburg, Pennsylvania, 17043
About this study
Official title: Sensible Medical Innovations (Noninvasive) Lung fLuid Status Monitor Allows rEducing Readmission Rate of Heart Failure Patients- a Randomized Controlled Study
Multi center, randomized controlled study, to determine if a significant decrease in the rate of heart failure re-hospitalizations occurs during a follow-up period when - ReDS guided treatment is used as an adjunct to standard of care.
Read the detailed description
The study is designed as a prospective, randomized, controlled, multi-center trial. Patients will be enrolled during an index hospitalization for Acutely decompensated Heart Failure (ADHF) and will be followed for a minimum of 3 months or a maximum of 9 months (until the last patient has completed the 3- month follow-up). Patients will be blinded to ReDS readings values.
Recruitment will take place either during a heart failure hospitalization (see acceptance criteria below) or within 10 days after discharge from a qualifying heart failure hospitalization.
The Remote Dielectric Sensing (ReDS) device provides noninvasive measurement of lung fluid content. It comprises a wearable vest with embedded sensors and a bedside console. A measurement reading is provided within 90sec. Results are shared with the treating physician via a secured web portal.
Study objective is to determine if a significant decrease in the rate of heart failure re-hospitalizations occurs during the entire follow-up period when ReDS guided treatment is used as an adjunct to standard of care (SOC).
Patients will be randomized between two groups before hospital discharge to: ReDS with SOC vs. SOC.
Patient that are randomized to the treatment arm will perform daily ReDS measurement at home. Treating physician will follow up on patients' measurements through a secured dedicated web site. Notification messages will be automatically sent by the system to the physician if certain thresholds are crossed (thresholds are physician adjustable). Medications will be adjusted according to defined guidelines.
Patients that are randomized to the control arm will be followed up and medically managed according to standard of care guidelines.
Both arms scheduled clinical visits and phone follow up:
- A follow up phone call, per current treatment guidelines, will be attempted within 2 days of hospital discharge to obtain information regarding medication reconciliation, Heart Failure (HF) symptoms and other HF management issues (e.g., dietary restrictions).
- An outpatient clinic visit will be scheduled after a week of hospital discharge.
- Study follow-up visits at 1 and 3 months. Follow-up will be continued for enrolled subjects at 6 and 9 months until the last subject has pass through the 3-month follow-up window.
- At each study follow-up visit, patients will undergo complete physical exam, vital signs, collection of readmission and standard blood tests and QOL questionnaire.
- Conditions
- Heart Failure
- Being tested
- Remote Dielectric Sensing (ReDS) Wearable System
- Keywords
- Heart Failure, Remote Patient Monitoring, Non Invasive Lung Fluid Status Monitor
- Medical subject headings
- Heart Failure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Remote Dielectric Sensing (ReDS) Wearable SystemDevice
Also called ReDS, Wearable Vest
The ReDS device provides noninvasive measurement of lung fluid content. It comprises a wearable vest with embedded sensors and a bedside console, with touch-screen display. A measurement reading is provided within 90sec. Results are shared with the treating physician via a secured web portal.
| Study group | Role | What they receive |
|---|---|---|
| ReDS Guided Treatment | Experimental | After discharge from hospital, patient will perform daily ReDS measurement. Data is automatically transmitted to the secured web portal. Treating physician will follow up on patients' measurements through a secured dedicated web site. Notification messages will be automatically sent by the system to the physician if certain thresholds are crossed (thresholds are physician adjustable). Medications will be adjusted according to defined guidelines. During the study a service center will monitor and support patient adherence and investigators attending to patients' notifications. Receives: Device: Remote Dielectric Sensing (ReDS) Wearable System |
| Standard of Care- Control arm | Active comparator | After discharge from hospital, patient will be followed up and medically managed according to standard of care guidelines. Receives: Device: Remote Dielectric Sensing (ReDS) Wearable System |
What is being measured
The primary outcome is the main question the study is designed to answer.
The rate of recurrent events of HF readmissions
Measured: Entire follow-up period (Expected average of 6.5 months)
Secondary outcomes (3)
Time from discharge until the first event of HF readmissions
Measured: Time to event (from discharge until the date of first event of HF readmissions, assessed up to 6.5 months)
Proportions of total days lost to hospitalization due to HF events
Measured: Entire follow-up period (Expected average of 6.5 months)
Time from discharge until all-cause mortality
Measured: time to event (from time of discharge until the date of first event of HF readmissions, assessed up to 6.5 months)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 May 2015 (estimated)
- Study startSep 2015
- Primary completion30 Nov 2017
- Study completion30 Nov 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Heart FailureStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 380 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sensible Medical Innovations Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- William Abraham, MD, Principal investigator, Ohio State UniversityAharon (Ronnie) Abbo, MD, Study director, Sensible Medical Innovations Ltd.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02448342
- Sponsor's protocol ID
- CL-00100-P
- Acronym
- SMILE™
- Status last verified
- Aug 2017
- First submitted
- 10 May 2015
- Last updated
- 29 Dec 2017
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Amir O, Rappaport D, Zafrir B, Abraham WT. A novel approach to monitoring pulmonary congestion in heart failure: initial animal and clinical experiences using remote dielectric sensing technology. Congest Heart Fail. 2013 May-Jun;19(3):149-55. doi: 10.1111/chf.12021. Epub 2013 Jan 25.
PubMed 23350643Amir O, Azzam ZS, Gaspar T, Faranesh-Abboud S, Andria N, Burkhoff D, Abbo A, Abraham WT. Validation of remote dielectric sensing (ReDS) technology for quantification of lung fluid status: Comparison to high resolution chest computed tomography in patients with and without acute heart failure. Int J Cardiol. 2016 Oct 15;221:841-6. doi: 10.1016/j.ijcard.2016.06.323. Epub 2016 Jul 1.
PubMed 27434357Amir O, Ben-Gal T, Weinstein JM, Schliamser J, Burkhoff D, Abbo A, Abraham WT. Evaluation of remote dielectric sensing (ReDS) technology-guided therapy for decreasing heart failure re-hospitalizations. Int J Cardiol. 2017 Aug 1;240:279-284. doi: 10.1016/j.ijcard.2017.02.120. Epub 2017 Mar 3.
PubMed 28341372
Study at a glance
From the registry record, last updated by the sponsor on 29 Dec 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Sensible Medical Innovations (Noninvasive) Lung fLuid Status Monitor Allows rEducing Readmission Rate of Heart Failure Patients- a Randomized Controlled Study
- ClinicalTrials.gov ID
- NCT02448342
- Acronym / sponsor ID
- SMILE™ / CL-00100-P
- Conditions
- Heart Failure
- Keywords
- Heart Failure, Remote Patient Monitoring, Non Invasive Lung Fluid Status Monitor
- Study type
- Interventional
- Recruitment status
- Terminated
- Enrolment
- 380 participants (estimated)
- Lead sponsor
- Sensible Medical Innovations Ltd.Industry (pharma, biotech, devices)
- Study start
- Sep 2015 (actual)
- Primary completion
- 30 Nov 2017 (actual)
- Study completion
- 30 Nov 2017 (actual)
- First posted
- 19 May 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Multi center, randomized controlled study, to determine if a significant decrease in the rate of heart failure re-hospitalizations occurs during a follow-up period when - ReDS guided treatment is used as an adjunct to standard of care.
Detailed description
The study is designed as a prospective, randomized, controlled, multi-center trial. Patients will be enrolled during an index hospitalization for Acutely decompensated Heart Failure (ADHF) and will be followed for a minimum of 3 months or a maximum of 9 months (until the last patient has completed the 3- month follow-up). Patients will be blinded to ReDS readings values.
Recruitment will take place either during a heart failure hospitalization (see acceptance criteria below) or within 10 days after discharge from a qualifying heart failure hospitalization.
The Remote Dielectric Sensing (ReDS) device provides noninvasive measurement of lung fluid content. It comprises a wearable vest with embedded sensors and a bedside console. A measurement reading is provided within 90sec. Results are shared with the treating physician via a secured web portal.
Study objective is to determine if a significant decrease in the rate of heart failure re-hospitalizations occurs during the entire follow-up period when ReDS guided treatment is used as an adjunct to standard of care (SOC).
Patients will be randomized between two groups before hospital discharge to: ReDS with SOC vs. SOC.
Patient that are randomized to the treatment arm will perform daily ReDS measurement at home. Treating physician will follow up on patients' measurements through a secured dedicated web site. Notification messages will be automatically sent by the system to the physician if certain thresholds are crossed (thresholds are physician adjustable). Medications will be adjusted according to defined guidelines.
Patients that are randomized to the control arm will be followed up and medically managed according to standard of care guidelines.
Both arms scheduled clinical visits and phone follow up:
- A follow up phone call, per current treatment guidelines, will be attempted within 2 days of hospital discharge to obtain information regarding medication reconciliation, Heart Failure (HF) symptoms and other HF management issues (e.g., dietary restrictions).
- An outpatient clinic visit will be scheduled after a week of hospital discharge.
- Study follow-up visits at 1 and 3 months. Follow-up will be continued for enrolled subjects at 6 and 9 months until the last subject has pass through the 3-month follow-up window.
- At each study follow-up visit, patients will undergo complete physical exam, vital signs, collection of readmission and standard blood tests and QOL questionnaire.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| ReDS Guided Treatment | Experimental | Device: Remote Dielectric Sensing (ReDS) Wearable SystemAfter discharge from hospital, patient will perform daily ReDS measurement. Data is automatically transmitted to the secured web portal. Treating physician will follow up on patients' measurements through a secured dedicated web site. Notification messages will be automatically sent by the system to the physician if certain thresholds are crossed (thresholds are physician adjustable). Medications will be adjusted according to defined guidelines. During the study a service center will monitor and support patient adherence and investigators attending to patients' notifications. |
| Standard of Care- Control arm | Active comparator | Device: Remote Dielectric Sensing (ReDS) Wearable SystemAfter discharge from hospital, patient will be followed up and medically managed according to standard of care guidelines. |
Who may qualify
- Ages
- 21 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Remote Dielectric Sensing (ReDS) Wearable SystemAlso: ReDS, Wearable VestThe ReDS device provides noninvasive measurement of lung fluid content. It comprises a wearable vest with embedded sensors and a bedside console, with touch-screen display. A measurement reading is provided within 90sec. Results are shared with the treating physician via a secured web portal. | Device | ReDS Guided Treatment, Standard of Care- Control arm |
Primary outcome
The rate of recurrent events of HF readmissions
Time frame: Entire follow-up period (Expected average of 6.5 months)
3 secondary outcomes
Time from discharge until the first event of HF readmissions
Time frame: Time to event (from discharge until the date of first event of HF readmissions, assessed up to 6.5 months)
Proportions of total days lost to hospitalization due to HF events
Time frame: Entire follow-up period (Expected average of 6.5 months)
Time from discharge until all-cause mortality
Time frame: time to event (from time of discharge until the date of first event of HF readmissions, assessed up to 6.5 months)
Results and safety
The study was stopped early. Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Dec 2017.
- Background: PubMed 23350643Amir O, Rappaport D, Zafrir B, Abraham WT. A novel approach to monitoring pulmonary congestion in heart failure: initial animal and clinical experiences using remote dielectric sensing technology. Congest Heart Fail. 2013 May-Jun;19(3):149-55. doi: 10.1111/chf.12021. Epub 2013 Jan 25.
- Background: PubMed 27434357Amir O, Azzam ZS, Gaspar T, Faranesh-Abboud S, Andria N, Burkhoff D, Abbo A, Abraham WT. Validation of remote dielectric sensing (ReDS) technology for quantification of lung fluid status: Comparison to high resolution chest computed tomography in patients with and without acute heart failure. Int J Cardiol. 2016 Oct 15;221:841-6. doi: 10.1016/j.ijcard.2016.06.323. Epub 2016 Jul 1.
- Background: PubMed 28341372Amir O, Ben-Gal T, Weinstein JM, Schliamser J, Burkhoff D, Abbo A, Abraham WT. Evaluation of remote dielectric sensing (ReDS) technology-guided therapy for decreasing heart failure re-hospitalizations. Int J Cardiol. 2017 Aug 1;240:279-284. doi: 10.1016/j.ijcard.2017.02.120. Epub 2017 Mar 3.
- Sponsor web siteLink provided by the sponsor.
Related trials for Heart Failure
RecruitingPhase 4
The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF)
Heart Failure With Reduced Ejection Fraction, Iron Deficiency
Not yet recruitingPhase 2
A Study of Bimagrumab in Participants With HFpEF
Heart Failure, Diastolic, Diastolic Heart Failure
Recruiting
Evaluation of a French Hospital Discharge Therapeutic Education Program by Nurses for Heart Failure Patient (EduSor)
Heart Failure
Active, not recruiting
Assessment of Combined CCM and ICD Device in HFrEF
Heart Failure, Heart Failure With Reduced Ejection Fraction
Not yet recruiting
RELIEVE-HFrEF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure With Reduced EF
Heart Failure and Reduced Ejection Fraction, Heart Failure Chronic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
William Abraham, MD principal investigator
Ohio State University
Aharon (Ronnie) Abbo, MD study director
Sensible Medical Innovations Ltd.
41 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Remote Dielectric Sensing (ReDS) Wearable System in people with Heart Failure, run by Sensible Medical Innovations Ltd. at 41 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 29 Dec 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 41 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early. Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The rate of recurrent events of HF readmissions (time frame: Entire follow-up period (Expected average of 6.5 months)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02448342, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Dec 2017.